Literature DB >> 16974196

Naturalistic long-term use of methylphenidate in bipolar disorder.

Eric Lydon1, Rif S El-Mallakh.   

Abstract

Antidepressant use seems to be problematic in bipolar disorder. The dopaminergic agent, bupropion, seems to be equally effective to serotoninergic agents but with greater safety. Methylphenidate is a stimulant medication that is sometimes used as an antidepressant in bipolar adults and is frequently used in children with comorbid bipolar and attention-deficit disorder. There are no data available for the safety of long-term methylphenidate in adults. A retrospective chart review of bipolar patients who received methylphenidate while attending a bipolar clinic was conducted. Data regarding side effects and symptoms were collected. Sixteen charts were reviewed. The mean duration of methylphenidate treatment was 14 months (+/-SD, +/-17.5 months; range, 1-60 months). Five had comorbid attention-deficit disorder, the remainder received the methylphenidate for depression. The mean dose was 16.3 mg/d (+/-SD, +/-8.7 mg/d; range, 5-40 mg/d). Several mild to moderate side effects were reported. Two patients (12.5%) discontinued methylphenidate because of adverse side effects. When available (44% of the sample), general assessment of function increased from (+/-SD) 48.3 +/- 9.9 to 69.3 +/- 10.6 (P = 0.006). Methylphenidate seems to be safe in the naturalistic setting. Controlled studies are needed to confirm its efficacy and safety in bipolar depression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16974196     DOI: 10.1097/01.jcp.0000236655.62920.dc

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  8 in total

Review 1.  Use of Stimulants in Bipolar Disorder.

Authors:  Giulio Perugi; Giulia Vannucchi; Fulvio Bedani; Ettore Favaretto
Journal:  Curr Psychiatry Rep       Date:  2017-01       Impact factor: 5.285

2.  Do stimulants protect against psychiatric disorders in youth with ADHD? A 10-year follow-up study.

Authors:  Joseph Biederman; Michael C Monuteaux; Thomas Spencer; Timothy E Wilens; Stephen V Faraone
Journal:  Pediatrics       Date:  2009-07       Impact factor: 7.124

Review 3.  Assessing the roles of stimulants/stimulant-like drugs and dopamine-agonists in the treatment of bipolar depression.

Authors:  Bernardo Dell'Osso; Terence A Ketter; Laura Cremaschi; Gregorio Spagnolin; A Carlo Altamura
Journal:  Curr Psychiatry Rep       Date:  2013-08       Impact factor: 5.285

4.  Suicidal and non-suicidal self-injurious behaviour in patients with bipolar disorder and comorbid attention deficit hyperactivity disorder after initiation of central stimulant treatment: a mirror-image study based on the LiSIE retrospective cohort.

Authors:  Louise Öhlund; Michael Ott; Robert Lundqvist; Mikael Sandlund; Ellinor Salander Renberg; Ursula Werneke
Journal:  Ther Adv Psychopharmacol       Date:  2020-08-06

5.  [Manic behavior as an autoregulatory attempt to stabilize vigilance].

Authors:  U Hegerl; S Olbrich; P Schönknecht; C Sander
Journal:  Nervenarzt       Date:  2008-11       Impact factor: 1.214

6.  Bipolar disorder: clinical perspectives and implications with cognitive dysfunction and dementia.

Authors:  R Lopes; L Fernandes
Journal:  Depress Res Treat       Date:  2012-05-28

7.  Current and emerging therapies for the management of bipolar disorders.

Authors:  Rif S El-Mallakh; Ahmed Z Elmaadawi; Yonglin Gao; Kavita Lohano; R Jeannie Roberts
Journal:  J Cent Nerv Syst Dis       Date:  2011-08-07

Review 8.  The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment.

Authors:  A H Ashok; T R Marques; S Jauhar; M M Nour; G M Goodwin; A H Young; O D Howes
Journal:  Mol Psychiatry       Date:  2017-03-14       Impact factor: 15.992

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.